GSC
TRVI icon

Ground Swell Capital’s Trevi Therapeutics TRVI Stock Holding History

Ground Swell Capital’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,461
Closed -$8K – 109
2021
Q4 		$8K Buy
+10,461
New +$11K 0.05% 65

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ground Swell Capital's TRVI Position: Q1 2022 in Review

Ground Swell Capital sold out of Trevi Therapeutics (TRVI) in Q1 2022, closing a stake of 10,461 shares — an estimated $8K sold.

Ground Swell Capital first reported a position in TRVI in Q4 2021 and held it in 1 quarter. The position peaked at $8K in Q4 2021. 23 funds tracked by Wall St. Rank hold TRVI as of Q1 2022.

  • Ground Swell Capital reported no remaining Trevi Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ground Swell Capital sold 10,461 Trevi Therapeutics shares in Q1 2022, an estimated $8K.
  • Ground Swell Capital first reported a position in Trevi Therapeutics in Q4 2021 and held it in 1 quarter.
  • Ground Swell Capital's Trevi Therapeutics position peaked at $8K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2022.

Based on Ground Swell Capital's 13F filing for Q1 2022, filed 10 May 2022.